Keyphrases
Pulmonary Function
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Graft-versus-host Disease (GvHD)
100%
Bortezomib
100%
Disease Diagnosis
25%
Tolerability
25%
FEV1 Decline
25%
Multiple Myeloma
12%
Protease Inhibitors
12%
Open-label Trial
12%
Pulmonary Function Test
12%
Safety Study
12%
Large Trials
12%
Adverse Events
12%
Multiple Myeloma Patients
12%
Pulmonary Toxicity
12%
Treatment Duration
12%
No Significant Difference
12%
Safety Analysis
12%
Acceptable Safety
12%
Allogeneic HSCT
12%
Early Dropout
12%
Immunology and Microbiology
Lung Function
100%
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Chronic Graft Versus Host Disease
100%
Multiple Myeloma
28%
Proteasome
14%
Pharmacology, Toxicology and Pharmaceutical Science
Bortezomib
100%
Chronic Graft Versus Host Disease
87%
Tolerability
25%
Multiple Myeloma
25%
Adverse Event
12%
Lung Toxicity
12%
Open-Label Trial
12%
Proteasome Inhibitor
12%